Cathay Wagantall on Questions Passed as Orders for Returns

With regard to government approval of the mixing and matching of COVID-19 vaccines (heterologous vaccination): (a) what data did the manufacturers of the Pfizer, Moderna and AstraZeneca COVID-19 vaccines have with respect to mixing their products with other COVID-19 vaccine products; (b) in mid-2021, when Health Canada (HC), the Public Health Agency of Canada (PHAC) and the National Advisory Committee on Immunization (NACI) were recommending mixing vaccines to Canadians, what did the Pfizer, Moderna and AstraZeneca COVID-19 vaccine monographs recommend at that same time; (c) what scientific rationale did HC, the PHAC and the NACI have for heterologous vaccination, broken down by (i) Pfizer mRNA vaccine and Moderna mRNA vaccine, (ii) mRNA vaccine and adenovirus vaccine; (d) what advice or instruction did the government receive from the World Health Organization’s Chief Scientist, Dr. Soumy Swaminathan, regarding the safety and efficacy of this approach in July 2021; (e) with respect to the advice in (d), did HC follow that advice and, if not, why not; (f) what data regarding the safety and risks of heterologous vaccination in Canadians (i) did the PHAC, the NACI or HC have at the time mixing was recommended, (ii) does the PHAC, the NACI or HC have currently; (g) with respect to the Canadian study related to the mixing and matching of COVID-19 vaccines, when will the results of the MOSAIC trials (CT24) NCT04894435 sponsored by the Canadian Immunization Research Network become available; (h) with respect to the study in (g), what are the interim results; and (i) with respect to the study in (g), what are the final results, if anything?